Severe Acute Respiratory Syndrome Coronavirus 2 From Patient With Coronavirus Disease, United States

Jennifer Harcourt; Azaibi Tamin; Xiaoyan Lu; Shifaq Kamili; Senthil K. Sakthivel; Janna Murray; Krista Queen; Ying Tao; Clinton R. Paden; Jing Zhang; Yan Li; Anna Uehara; Haibin Wang; Cynthia Goldsmith; Hannah A. Bullock; Lijuan Wang; Brett Whitaker; Brian Lynch; Rashi Gautam; Craig Schindewolf; Kumari G. Lokugamage; Dionna Scharton; Jessica A. Plante; Divya Mirchandani; Steven G. Widen; Krishna Narayanan; Shinji Makino; Thomas G. Ksiazek; Kenneth S. Plante; Scott C. Weaver; Stephen Lindstrom; Suxiang Tong; Vineet D. Menachery; Natalie J. Thornburg

Disclosures

Emerging Infectious Diseases. 2020;26(6):1266-1273. 

In This Article

Discussion

We have deposited information on the SARS-CoV-2 USA-WA1/2020 viral strain described here into the Biodefense and Emerging Infections Research Resources Repository (https://www.beiresources.org) reagent resources (American Type Culture Collection, https://www.atcc.org) and the World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch (https://www.utmb.edu/wrceva), to serve as the SARS-CoV-2 reference strain for the United States. The SARS-CoV-2 fourth passage virus has been sequenced and maintains a nucleotide sequence identical to that of the original clinical strain from the United States. These deposits make this virus strain available to the domestic and international public health, academic, and pharmaceutical sectors for basic research, diagnostic development, antiviral testing, and vaccine development. We hope broad access will expedite countermeasure development and testing and enable a better understanding of the transmissibility and pathogenesis of this novel emerging virus.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....